Role of B Lymphocytes in the Pathogenesis of Type 1 Diabetes
- 1.3k Downloads
Though type 1 diabetes (T1D) is considered a T cell-mediated autoimmune disorder, recent evidence indicates that B cells play a critical role in disease. This conclusion is based in part on the success of anti-CD20 (rituximab) therapy, which by broadly depleting B cells delays disease progression in non-obese diabetic (NOD) mice and new-onset patients. B cell receptor (BCR) specificity to islet autoantigen is key. NOD mice whose B cell repertoire is biased toward insulin reactivity show increased disease development, while bias away from insulin reactivity largely prevents disease. Although the operative disease-promoting B cell effector function remains undefined, islet-antigen reactive B cells function in antigen presentation to diabetogenic CD4 T cells. Other studies implicate B cells in antigen presentation to CD8 T cells. B cell participation in TID appears predicated on faulty B cell tolerance. Here, we review extant findings implicating B cells in T1D in mice and men.
KeywordsImmune pathology B lymphocyte Antigen presentation
Compliance with Ethics Guidelines
Conflict of Interest
Rochelle M. Hinman and John C. Cambier declare that they have no conflict of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 8.••Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, Becker DJ, Gitelman SE, Goland R, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143–52. Seminal clinical study shows that anti-CD20 (Rituximab) therapy, which by broadly depleting B cells can delay disease progression in new onset human patients.PubMedCrossRefGoogle Scholar
- 21.••Cox SL, Stolp J, Hallahan NL, Counotte J, Zhang W, Serreze DV, et al. Enhanced responsiveness to T-cell help causes loss of B-lymphocyte tolerance to a beta-cell neo-self-antigen in type 1 diabetes prone NOD mice. Eur J Immunol. 2010;40(12):3413–25. doi: 10.1002/eji.201040817. Prior studies of NOD B cell tolerance using mice transgenic for both anti-hen egg lysozyme (HEL) BCR and HEL autoantigen expressed HEL systemically. Here autoantigen expression is driven by the insulin promoter and confined to the pancreas. Thus, it is a far more physiologically relevant model to understand the roots of T1D pathogenesis.PubMedCrossRefGoogle Scholar
- 29.••Habib T, Funk A, Rieck M, Brahmandam A, Dai X, Panigrahi AK, et al. Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. J Immunol. 2012;188(1):487–96. doi: 10.4049/jimmunol.1102176. Seminal work showing a human PTPN22 variant is capable of altering the integrity of B cell tolerance and ultimately increasing the risk of T1D.PubMedCentralPubMedCrossRefGoogle Scholar
- 35.Bonifacio E, Atkinson M, Eisenbarth G, Serreze D, Kay TW, Lee-Chan E, et al. International Workshop on Lessons From Animal Models for Human Type 1 Diabetes: identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice. Diabetes. 2001;50(11):2451–8.PubMedCrossRefGoogle Scholar
- 38.••Garabatos N, Alvarez R, Carrillo J, Carrascal J, Izquierdo C, Chapman HD, et al. In vivo detection of peripherin-specific autoreactive B cells during type 1 diabetes pathogenesis. J Immunol. 2014;192(7):3080–90. doi: 10.4049/jimmunol.1301053. Prior to publication of this paper, insulin-specfic B cells were the only islet autoantigen specific B cells identified in the NOD mouse model. Though the importance of peripherin as a pancreatic antigen remains to be determined, the presence of the these B cells in the pancreas is an intriguing finding.PubMedCrossRefGoogle Scholar
- 40.•Marino E, Tan B, Binge L, Mackay CR, Grey ST. B-cell cross-presentation of autologous antigen precipitates diabetes. Diabetes. 2012;61(11):2893–905. doi: 10.2337/db12-0006. A clear demonstration of the importance of B cells in cross presenting autoantigen to self-reactive CD8+ T cells.PubMedCentralPubMedCrossRefGoogle Scholar
- 43.•Kendall PL, Case JB, Sullivan AM, Holderness JS, Wells KS, Liu E, et al. Tolerant anti-insulin B cells are effective APCs. J Immunol. 2013;190(6):2519–26. doi: 10.4049/jimmunol.1202104. Though the study is largely an in vitro demonstration of antigen presentation, it does show that insulin-binding 125Tg B cells are more competent presenters of insulin peptides than their non insulin-binding counterparts. Suggesting they may be in vivo potent antigen presenting cells as well.PubMedCentralPubMedCrossRefGoogle Scholar
- 48.Alanentalo T, Loren CE, Larefalk A, Sharpe J, Holmberg D, Ahlgren U. High-resolution three-dimensional imaging of islet-infiltrate interactions based on optical projection tomography assessments of the intact adult mouse pancreas. J Biomed Opt. 2008;13(5):054070. doi: 10.1117/1.3000430.PubMedCrossRefGoogle Scholar
- 52.••Di Caro V, Phillips B, Engman C, Harnaha J, Trucco M, Giannoukakis N. Involvement of suppressive B-lymphocytes in the mechanism of tolerogenic dendritic cell reversal of type 1 diabetes in NOD mice. PLoS One. 2014;9(1):e83575. doi: 10.1371/journal.pone.0083575. Seminal demonstration of how tolerogenic dendritic cells may be exploited to expand a population of immunosuppressive B cells, widely referred to as B-regulatory cells (Bregs) and suppress T1D.PubMedCentralPubMedCrossRefGoogle Scholar
- 53.Montandon R, Korniotis S, Layseca-Espinosa E, Gras C, Megret J, Ezine S, et al. Innate pro-B-cell progenitors protect against type 1 diabetes by regulating autoimmune effector T cells. Proc Natl Acad Sci U S A. 2013;110(24):E2199–208. doi: 10.1073/pnas.1222446110.PubMedCentralPubMedCrossRefGoogle Scholar
- 55.•Henry RA, Kendall PL, Thomas JW. Autoantigen-specific B-cell depletion overcomes failed immune tolerance in type 1 diabetes. Diabetes. 2012;61(8):2037–44. doi: 10.2337/db11-1746. Model approach of how specific targeting of B cells that recognize islet antigens effects disease development.PubMedCentralPubMedCrossRefGoogle Scholar